Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

284
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
284
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

1.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.2K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

491
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
491
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.8K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

749
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
749

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NMM-promoted decarboxylative C(sp<sup>3</sup>)-C(sp<sup>3</sup>) coupling of coumarin-3-carboxylic acids and indolin-3-ones.

Organic & biomolecular chemistry·2026
Same author

Comparing terror management and time management: The effects of mortality awareness on time perception, delay discounting, and monetary allocation.

Acta psychologica·2026
Same author

Decoupling Site-Selective CO Poisoning From Hydrogen Oxidation Activity on Pt/C in PEMFCs.

Angewandte Chemie (International ed. in English)·2026
Same author

Development and validation of a self-management efficacy questionnaire for patients with Fabry disease in China.

Annals of medicine·2026
Same author

Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication: A Meta-Analysis.

Journal of gastroenterology and hepatology·2026
Same author

Probiotics in the treatment of helicobacter pylori infection: A bibliometric analysis from 2001 to 2025.

Journal of infection and public health·2026
Same journal

A platelet-monocyte pyroptotic axis mediates uremic cardiomyopathy: critical role of PF4 and hematopoietic caspase-1.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same journal

Single-cell transcriptomic analysis identifies a MIF-driven keratinocyte-macrophage-Th2 axis as a key inflammatory circuit in atopic dermatitis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same journal

Agmatine induces mitophagy via the PTS-I2R pathway to increase autophagic flux and attenuate sepsis-induced intestinal epithelial cell apoptosis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same journal

Eosinophil cationic protein-driven type 2 inflammation impairs olfactory function in a murine model.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same journal

Spleen-associated macrophage alterations and embryo viability in a murine model of recurrent spontaneous abortion.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same journal

Chronic intermittent hypoxia sustains the low-grade inflammatory memory of monocytes via activation of myelopoiesis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K

Luteolin alleviates ulcerative colitis through SHP-1/STAT3 pathway.

Bo-Lin Li1, Dan-Yang Zhao1, Peng-Li Du1

  • 1Department of Gastroenterology, Hebei Provincial Hospital of Chinese Medicine, No. 389, Zhongshan East Road, Chang an District, Shijiazhuang, 050011, Hebei, People's Republic of China.

Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|May 20, 2021
PubMed
Summary
This summary is machine-generated.

Luteolin enhances intestinal barrier function by increasing tight junction proteins and reducing inflammation. This natural compound may protect the gut by inhibiting the STAT3 signaling pathway via SHP-1.

Keywords:
LuteolinSHP-1STAT3Tight junctionUlcerative colitis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1000

Related Experiment Videos

Last Updated: Nov 5, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1000

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Pharmacology

Background:

  • Luteolin is known to improve epithelial barrier integrity.
  • The precise mechanism of Luteolin's action on the intestinal barrier remains unclear.
  • This study investigates Luteolin's effects and regulatory mechanisms in intestinal epithelial barrier integrity.

Purpose of the Study:

  • To explore the effects of Luteolin on intestinal epithelial barrier integrity.
  • To elucidate the underlying regulatory mechanism of Luteolin's action.
  • To evaluate Luteolin's therapeutic potential in ulcerative colitis.

Main Methods:

  • Caco-2 cell monolayers were treated with TNF-α, IFN-γ, and Luteolin.
  • SHP-1 (protein phosphoserine phosphatase-1) expression was manipulated (overexpression/knockdown).
  • Barrier function was assessed using TEER and FITC-dextran assays, with molecular analysis via qRT-PCR and Western blot. An in vivo ulcerative colitis model was also used.

Main Results:

  • Luteolin treatment increased Caco-2 monolayer resistance and expression of tight junction proteins (OCLN, CLDN1, ZO1), while decreasing CLDN2.
  • Overexpression of SHP-1 enhanced epithelial barrier function; SHP-1 knockdown or STAT3 inhibition negated Luteolin's protective effects.
  • Luteolin significantly alleviated symptoms in a DSS-induced mouse model of ulcerative colitis.

Conclusions:

  • Luteolin treatment promotes intestinal epithelial barrier function.
  • Luteolin preserves intestinal barrier integrity potentially by inhibiting the STAT3 signaling pathway through SHP-1.
  • These findings highlight Luteolin as a potential therapeutic agent for intestinal barrier dysfunction.